Minerva Neurosciences (NERV) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Minerva Neurosciences (NERV) over the past year, losing 38.0% versus a loss of 49.2%. Over five years, NERV leads with a -76.4% price change compared with -88.5% for UNCY. Minerva Neurosciences is the larger company by market cap ($99.7 million vs $97.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | UNCY |
|---|---|---|
| Share price | $2.00 | $3.35 |
| Market cap | $99.67M | $97.77M |
| 1-day change | -5.66% | -5.10% |
| YTD return | -50.25% | -41.94% |
| 1-year return | -49.24% | -37.96% |
| 5-year return | -76.42% | -88.53% |
| Forward P/E | — | 4.86 |
| EPS (TTM) | $-33.83 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-293.42M | $-26.55M |
| 52-week high | $8.80 | $8.74 |
| 52-week low | $1.96 | $3.33 |
| Distance from 52-week high | -77.27% | -61.67% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +416.50% | +685.07% |
| Average volume | 164.71K | 963.80K |
| Shares outstanding | 49.84M | 29.18M |
| Employees | 7 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed NERV by 11.3 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NERV vs UNCY FAQ
Which is bigger, Minerva Neurosciences or Unicycive Therapeutics?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $99.67M compared with $97.77M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, NERV or UNCY?
UNCY returned -37.96% over the past 12 months, compared with -49.24% for NERV (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.